Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Cablivi addresses a critical unmet need in patients facing acquired thrombotic thrombocytopenic purpura

  80% confidence

• This innovation offers people with hemophilia A or B, with or without inhibitors, a new therapeutic option by lowering antithrombin levels to restore coagulation balance

  80% confidence

• Qfitlia has the potential to make prophylaxis more accessible to people with hemophilia worldwide by offering effective bleeding protection and simplified administration

  80% confidence

• Qfitlia potentially requiring only six subcutaneous injections per year significantly reduces disease burden, eliminating the need for frequent intravenous injections associated with traditional factor treatment

  80% confidence

• These approvals mark a new milestone in Sanofi's long-term commitment to China, reinforcing the company's ambition to bring transformative medicines across various therapeutic areas

  80% confidence

• Qfitlia approval marks a true transition to a new era of non-factor prophylactic treatment for hemophilia in China

  80% confidence

• Qfitlia represents a potentially transformative advancement for the hemophilia community in China, evolving care from treating bleeds as they occur to a comprehensive preventive approach

  80% confidence

• These approvals underscore Sanofi's commitment to bringing significant innovations and improving the lives of people with rare diseases in China and worldwide

  80% confidence

Data points we hold from this source